Papers by Francesco Angrilli
British Journal of Haematology, 2012
Haematologica, 2000
The subset of non-follicular non-Hodgkin's lymphoma (NHL) includes patients with varied progn... more The subset of non-follicular non-Hodgkin's lymphoma (NHL) includes patients with varied prognoses, thus suitable for different therapeutic approaches. The International Prognostic Index (IPI), originally proposed for aggressive NHL, has been demonstrated to be of prognostic relevance also in follicular NHL. The main aim of the study was to validate the IPI in this histologic category; in addition, the specific prognostic classification, currently employed in the Gruppo Italiano per lo Studio dei Linfomi (GISL) prospective therapeutic trials and based on different features, more similar to those applied to chronic lymphocytic leukemia, was analyzed. The present series consists of 137 evaluable patients affected by Working Formulation group A NHL out of 256 cases referred to the GISL Registry. The retrospective prognostic study included the evaluation by both univariate and multivariate analyses of overall survival, response to therapy and response duration. The IPI was applied as...
Meccanica, 1975
Mutual interdependency between structural vibrations and fluid dynamic forces has been described ... more Mutual interdependency between structural vibrations and fluid dynamic forces has been described by several mathematical models, which are discussed and compared with a model, the basic idea of which is that hydrodynamic forces can be separately computed according to whether they depend on the body movement or exist even if the structure is steady. The 'time of vortex origin' is introduced as a fundamental element for characterizing these forces in amplitude and phase. The relevant equations have been applied to experiments in air and in water. The most important features of the phenomenon are satisfactorily reproduced by the mathematical model.
European journal of cancer (Oxford, England : 1990), Jan 26, 2016
Recently, encouraging results in terms of safety and efficacy have been obtained using bendamusti... more Recently, encouraging results in terms of safety and efficacy have been obtained using bendamustine-rituximab (BR) in untreated chronic lymphocytic leukaemia (CLL) patients enrolled in a phase II study. Here, we report a retrospective international multicenter study of CLL patients treated with BR as front-line therapy. The cohort included 279 patients with progressive CLL from 33 centers (29 Italian, 3 Israeli and 1 German) who received at least 1 cycle of BR as first-line treatment during the 2008-2014 period. The primary objective of this study was to evaluate the efficacy and safety of BR administered as front-line therapy, outside of controlled clinical trials. Median age was 70 years (range, 43-86 years); 62.4% were males and 35.8% had Binet stage C. Forty-two patients (15.2%) were unfit (cumulative illness rating scale [CIRS] score ā„7), and 140 (50.2%) had creatinine clearance ā¤70Ā ml/min. Fluorescent in situ hybridisation analysis, available for 192 cases, showed that 21 (10....
Ash Annual Meeting Abstracts, Nov 20, 2009
Ash Annual Meeting Abstracts, Nov 19, 2010
Ash Annual Meeting Abstracts, Nov 18, 2011
Haematologica, 2002
We treated 30 consecutive untreated patients aged &am... more We treated 30 consecutive untreated patients aged > 70 years with advanced aggressive non-Hodgkin's lymphoma with 6 courses of cyclophosphamide, mitoxantrone, etoposide, bleomycin, vinblastine and dexamethasone (D-VICEMB). The global response was 93%. The 6-year overall survival and progression-free survival were 50%, and disease-free survival was 63%.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Jan 28, 2015
The randomized HD2000 trial compared six cycles of ABVD (doxorubicin, bleomycin, vinblastine, and... more The randomized HD2000 trial compared six cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), four escalated plus two standard cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), and six cycles of COPP-EBV-CAD (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin; CEC) in patients with advanced-stage Hodgkin lymphoma. After a median follow-up of 42 months, patients who received BEACOPP were reported to have experienced better progression-free survival (PFS) but not better overall survival (OS) results than those receiving ABVD. We here report a post hoc analysis of this trial after a median follow-up of 10 years. Three hundred seven patients were enrolled, 295 of whom were evaluable. At the time of our analysis, the median follow-up for the entire group was 120 months (range, 4 to 169 months). The 10-year PFS results for th...
Ash Annual Meeting Abstracts, Nov 16, 2008
Http Dx Doi Org 10 1080 10428190600977690, Jul 1, 2009
Journal of Fluids Engineering
Haematologica, 2000
The subset of non-follicular non-Hodgkin's lymphoma (NHL) includes patients with varied progn... more The subset of non-follicular non-Hodgkin's lymphoma (NHL) includes patients with varied prognoses, thus suitable for different therapeutic approaches. The International Prognostic Index (IPI), originally proposed for aggressive NHL, has been demonstrated to be of prognostic relevance also in follicular NHL. The main aim of the study was to validate the IPI in this histologic category; in addition, the specific prognostic classification, currently employed in the Gruppo Italiano per lo Studio dei Linfomi (GISL) prospective therapeutic trials and based on different features, more similar to those applied to chronic lymphocytic leukemia, was analyzed. The present series consists of 137 evaluable patients affected by Working Formulation group A NHL out of 256 cases referred to the GISL Registry. The retrospective prognostic study included the evaluation by both univariate and multivariate analyses of overall survival, response to therapy and response duration. The IPI was applied as...
European journal of haematology, Jan 9, 2015
We performed an external and multicentric validation of the predictive value of abdominal compute... more We performed an external and multicentric validation of the predictive value of abdominal computed tomography (aCT) on time to first treatment (TTFT) in early-stage chronic lymphocytic leukaemia (CLL) patients. aCT was performed at diagnosis in 181 Rai 0 patients enrolled in the O-CLL1-GISLtrial (clinicaltrial. govID:NCT00917549). Fifty-five patients showed an abnormal aCT. Patients with an abnormal aCT showed a significantly shorter TTFT than those with normal aCT (P<.0001). At multivariate analysis, aCT (P=.011), Ī²-2 microglobulin (P=.019) and CD38 expression (P=.047) correlated with TTFT. Following IWCLL 2008 criteria, 112 (61.9%) cases remained at Rai 0, while 69 (38.1%) satisfied the criteria of clinical monoclonal B-cell lymphocytosis (cMBL). Reclassified Rai 0 patients with an abnormal aCT showed a significantly shorter TTFT than those with a normal aCT (P<.0001). At multivariate analysis, only aCT (P=.011) correlated with TTFT. Eleven cMBL cases (15.9%) showed an abnor...
Clinical Lymphoma Myeloma and Leukemia, 2011
Chemoresistance can be disclosed by incomplete response or early relapse. The tumor burden of Hod... more Chemoresistance can be disclosed by incomplete response or early relapse. The tumor burden of Hodgkin lymphoma was assessed in 115 patients treated with ABVD and 107 with BEACOPP and demonstrated to be the best predictor of resistance. For the same tumor burden ABVD has higher risk of resistance than BEACOPP and it should be considered in the choice of treatments. Background: The mature results from trials comparing ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, dacarbazine) and BEACOPP (bleomycin, etoposide, Adriamycin [doxorubicin], cyclophosphamide, Oncovin [vincristine], procarbazine, prednisone) chemotherapies in advanced Hodgkin lymphoma will be available in some years. An early comparison of their curative potential can however be obtained from an assessment of initial tumor burden and chemoresistance. Patients and Methods: Less than a complete remission after treatment and relapse occurring within 12 months thereafter were assumed to be clinical expressions of chemoresistance. The tumor burden was calculated from the measurements of all the lesions documented by staging computed tomography (CT) and was normalized to body surface area to give the relative tumor burden (rTB). Using logistic regression analysis, the relationship between initial rTB, chemoresistance, and chemotherapy regimen administered was retrospectively studied in 222 patients selected from those enrolled in 2 similar randomized trials. Results: The median rTB volumes were 157.9 cm 3 /m 2 in the 115 patients treated with ABVD vs. 154.6 cm 3 /m 2 in the 107 patients treated with BEACOPP, and the distribution of the volumes was identical in the 2 groups. The rTB was confirmed as the best predictor of early treatment failures (22 less than complete responses plus 21 early relapses). For the same rTB, the risk of chemoresistance to BEACOPP was about half that of the chemoresistance to ABVD or, for a given risk of chemoresistance, BEACOPP cured patients with an rTB 89.1 cm 3 /m 2 greater than that cured by ABVD (ie, more than 50% of the median tumor load of patients with advanced-stage disease). Conclusion: This account of rTB allows an early comparative evaluation of the curative ability of different chemotherapy regimens.
Leukemia & Lymphoma, 2002
At present we report the results of a prospective, non-randomized open trial, conducted on follic... more At present we report the results of a prospective, non-randomized open trial, conducted on follicular lymphoma (FL) patients by the Gruppo Italiano per lo Studio dei Linfomi (GISL), after a median follow-up of 62.6 months. Seventy-three patients with FL were registered to the study and treated with combination chemotherapy consisting of cyclophosphamide, epidoxorubicin, vincristine, bleomycin and prednisone, weekly administered every 4 weeks. After chemotherapy, involved-field radiotherapy was delivered in case of either localized, bulky and extranodal disease at presentation or limited residual disease at the end of chemotherapy. Patient received four or eight chemotherapy courses in case of localized or advanced disease, respectively. The overall response rate at the end of the treatment program was 97.3%, with 78.1% CR and 19.2% PR. CR rate was 94.3 and 63.1% in stage I-II and III-IV, respectively (p = 0.006). Beside the stage, response rate was significantly influenced by bone marrow involvement, and the number of extranodal sites. Relapse free survival was 60.8% at 5 years in the whole series; in localized disease it was 70.3 vs. 44.8% in advanced disease (p = 0.044). Relapse free survival was significantly influenced by stage, bone marrow involvement, number of extranodal sites and International Prognostic Index (IPI) score. The overall 5-year survival rate was 90.2%; being 95.6% for patients with stage I-II and 85.1% for those III-IV (p = 0.0133). In addition, both IPI and Italian Lymphoma Intergroup (ILI) score had a significant impact on survival. The toxicity profile of the treatment was acceptable. From the results of this prospective study it is possible to conclude that this regimen and the whole treatment program is effective as first line therapy for the general population of FL. In particular the BACOP schedule is a valid anthracycline-containing regimen, and in this respect suitable to be considered as a treatment option.
Leukemia & Lymphoma, 2007
Leukemia & Lymphoma, 2011
Leukemia & Lymphoma, 2008
We conducted a retrospective study on treatment-related ovarian failure in 61 women with Hodgkin ... more We conducted a retrospective study on treatment-related ovarian failure in 61 women with Hodgkin lymphoma who were under treatment from 1994 to 2006. To minimize the risk of treatment-related gonadotoxicity, triptorelin (Decapeptyl), a gonadotropin-releasing hormone analog (GnRHa), was administered monthly. All patients were treated with frontline polychemotherapy with or without radiotherapy. Seven refractory or relapsed patients received salvage treatment, and six of these patients further received peripheral blood stem cell transplantation. Fifty patients (82%) recovered regular menses, four patients (6%) reported menstrual abnormalities, and seven patients (12%) who were under salvage treatment became amenorrheic. We found a clear correlation between age at the time of treatment, advanced disease, cumulative therapeutic load and ovarian failure. After the completion of treatment, 13 patients who attempted conception conceived. GnRHa may preclude ovarian damage and infertility in young women receiving frontline polychemotherapy alone or in combination with supradiaphragmatic radiotherapy. In refractory or relapsed patients, GnRHa does not seem to be very effective, and further experimental approaches are required for fertility preservation.
Journal of Clinical Oncology, 2013
Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requi... more Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified.
Uploads
Papers by Francesco Angrilli